Disease landscape
Leukemia (AML)
Significant constraints in access to AML diagnosis and treatment have been identified in the Visegrád (V4) countries. The obtained scores place the indicator for AML at a medium level among all assessed diseases. Results vary from state to state - the difference between the highest and the lowest score exceeds 23 points. The main reason for the unsatisfactory performance of the V4 group in AML is limited access to novel drugs in all the V4 countries due to the lack of reimbursement or strict reimbursement criteria. The only areas that pull the total score up are relatively good access to AML diagnosis in the region and relatively decent time to availability (in relation to other diseases).
Cross-Country
General GAP for AML
Compliance with guidelines
Positive recommendations for 6 AML drugs were found in analysed clinical practice guidelines. At least 3 of them are available to AML patients in the V4 countries - compliance with the guidelines is assessed at 50-67%.
From registration to reimbursement
Population burden
DALY* - Rate per 100k
*disability adjusted life-years
Target population
Selected drugs
Drug access
Number of patients treated (2021)
Drug access
Population treated (%)
Main issues
- The average time to reimbursement for AML drugs in the V4 countries is almost 2.6 years. The difference between the shortest and the longest mean time to reimbursement among the countries is 0.9 year
- The uptake of selected novel drugs in a target population is highly differentiated and ranges from 2% in Poland and 17% in Hungary to 51-56% in Slovakia and Czechia.
- DALY (disability adjusted life-years) burden related to AML in the V4 countries is lower (up to 10%) than the European Union average.
Project
We measured the gap in innovative drug access and diagnostics in selected therapeutic areas in the Visegrád (V4) countries (Poland, Hungary, Czechia and Slovakia).